# Raltitrexed in Treating Children With Refractory Acute Leukemia

> **NCT00003528** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia

## Interventions

- **DRUG:** raltitrexed

## Key facts

- **NCT ID:** NCT00003528
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 2002-06
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003528, "Raltitrexed in Treating Children With Refractory Acute Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00003528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*